MaxCyte, Inc.

Reflecting on a high-powered week at the Genome Engineering: CRISPR Frontiers summit. Andrew Guy Mancini, our Senior Corporate Development Associate, co-presented a trailblazing poster with Kevin Holden from Synthego Corporation. What a groundbreaking exploration of gene-editing efficiencies in primary cells with MaxCyte electroporation and Synthego sgRNAs! An additional toast to Synthego, our partner in innovation and booth mates at the conference, and a huge shout-out to our collaborators at University of California, San Francisco and the The National Institutes of Health for their pivotal contributions to our case studies. Learn about how our scalable cGMP compliant electroporation technology can take your processes from concept to clinic. https://bit.ly/3ANncg2 #GeneEditing #Collaboration #Innovation #CRISPRFrontiers

Join us next week for our featured presentation exploring innovative cell engineering methods at Cancer Research Center in Lyon, France! Be sure to visit our booth from 9:00 - 2:00 to connect with Marie-Laure Joandel and Amandine Girard and learn how MaxCyte's innovative electroporation platforms enable the efficient engineering of primary cells, stem cells, and more. https://bit.ly/3XmmrCr

MaxCyte has teamed with ScaleReady, the cell therapy manufacturing solutions expert, to participate in their newly launched G-Rex® Grant Program. “The G-Rex® Grant Program represents a significant step forward in reducing the barrier to entry that many CGT companies encounter in cell and gene therapy development. Our involvement formalizes a long-standing relationship between MaxCyte and ScaleReady and ensures that G-Rex® Grant Recipients will benefit from our state-of-the-art electroporation technology and extensive expertise in cell therapy development,” said Maher Masoud, President and CEO of MaxCyte. Read the full announcement here: https://bit.ly/4cTe4UE

Pioneering safer and more efficient methods for therapy development is at the core of our mission. Our Senior Vice President, James Brady weighs in on the power of electroporation in revolutionizing CGT development. Not only efficiently delivering complex payloads but also minimizing health risks, providing a promising alternative to viral vectors. Take note of Vertex’s FDA-approved therapy, Casgevy, as an exemplar of this method. Dive into the conversation with the full feature article in Genetic Engineering & Biotechnology News here: https://lnkd.in/e8jcCEdm #Biotechnology #CGTDevelopment #Electroporation.

Join us tomorrow for #Genome Engineering: CRISPR Frontiers 2024 at the Cold Spring Harbor Laboratory, in New York! While there, make sure to visit poster 136 presented by Andrew Guy Mancini, PhD, and Kevin Holden from Synthego Corporation. In their poster they will show how combining MaxCyte's electroporation platform with Synthego gene editing tools can achieve high efficiency gene editing even in hard-to-transfect cells such as primary NK cells, primary keratinocytes, and primary macrophages. We look forward to connecting with you and learning more about your work! See you there! #cshlcrispr24 #CRISPR

Join us next week for our featured presentation exploring innovative cell engineering methods at Cancer Research Center in Lyon, France! Reserve your spot now to gain valuable insights into how MaxCyte's innovative electroporation platforms enable the efficient engineering of primary cells, stem cells, and many more cell lines. Discover how our technology guarantees high cell viability and optimal recovery rates for a wide range of applications, including CRISPR, cell-based assays, cell therapy manufacturing, viral production, and so much more. Marie-Laure Joandel and Amandine Girard look forward to connecting with you! https://bit.ly/3XmmrCr

Discover the energy and passion that drive our success at MaxCyte! At MaxCyte, we deeply value the voices of our team members, as they are integral to our success. Hear firsthand from our research scientist, Isabel Daher, as she shares what she loves about working at MaxCyte. Are you curious about being part of a team that values your voice? Explore our current job openings and apply today! https://bit.ly/46B9HvM

Join us next week for Genome Engineering: CRISPR Frontiers 2024 at the Cold Spring Harbor Laboratory, in New York! While there, make sure to visit poster 136 presented by Andrew Guy Mancini, PhD, and Kevin Holden from Synthego Corporation. In their poster they will show how combining MaxCyte's electroporation platform with Synthego gene editing tools can achieve high efficiency gene editing even in hard-to-transfect cells such as primary NK cells, primary keratinocytes, and primary macrophages. We look forward to connecting with you and learning more about your work! See you there! #cshlcrispr24 #CRISPR

🚨 Only 2 days left of the #CHIBioprocessingSummit! 🚨 Make sure to stop by our booth #104 to meet with me, Jess Keeley, Joseph White, and Daniel Miller. We're excited to show you how we can best support your Cell Therapy, Drug Discovery, & Bioprocessing needs! 🎤 Don't miss out! Join us today at 2:30 PM in Back Bay B where James Brady will be presenting on Streamlining Cell Therapy Manufacturing with Scalable, GMP-compliant Electroporation. Looking forward to connecting with you!

Be sure to join us today at 2:30 pm EST at the #CHIBioProcessingSummit for a stellar presentation by our Senior Vice President, Technical Applications & Customer Service, @James Brady! His presentation will discuss data showcasing MaxCyte’s clinically validated electroporation platform for the efficient delivery of CRISPR-based editing reagents, transposons, and other molecules to T cells, NK cells, macrophages, and more. Discover how our platform overcomes many of the challenges associated with other methods. We look forward to seeing you there! https://bit.ly/2ZCR6ic